Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Stroke Research

Study Title:  BrainsGate: A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Effectiveness and Safety of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects With Acute Ischemic Stroke (Phase III) (Identifier: NCT00826059)

Study Purpose:  The purpose of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.

Principal Investigator: Syed Zaidi, M.D.

Study Coordinator: Andrea Korsnack, RN, CNRN, CCRC.  For more information, please contact 419.383.3801.


Study Title:  Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial (Identifier: NCT00991029)

Study Purpose:  A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an NIH Stroke Scale [NIHSS] score less than or equal to 3). TIAs are common [25], and are often harbingers of disabling strokes. Composite endpoint of new ischemic vascular events: ischemic stroke, myocardial infarction or ischemic vascular death at 90 days.

Principal Investigator: Mouhammad Jumaa, M.D.

Study Coordinator: Andrea Korsnack, RN, CNRN, CCRC.  For more information, please contact 419.383.3801.


Study Title:  Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke (ACTION) (Identifier: NCT01955707)

Study Purpose:  The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) BG00002 reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in subjects with acute ischemic stroke when given at ≤6 hours or at >6 to ≤9 hours from when they were last known normal (LKN).

Principal Investigator: Mouhammad Jumaa, M.D.

Study Coordinator: Andrea Korsnack, RN, CNRN, CCRC.  For more information, please contact 419.383.3801.


 

Study Title:  A Phase IIIb, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients with Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS) (Identifier: NCT02072226)

Study Purpose:   PRISMS is a double-blind, multicenter, randomized, Phase IIIb study to evaluate the efficacy and safety of intravenous (IV) Activase in patients with mild acute ischemic strokes that do not appear to be clearly disabling.  Patients will be randomized in a 1:1 ratio to receive within 3 hours of last known well time either 1) one does of IV Activase and one does of oral aspirin placebo or 2) one dose of IV Activase placebo and one dose of oral aspirin 325 mg.

Principal Investigator: Syed Zaidi, M.D.

Study Coordinator: Andrea Korsnack, RN, CNRN, CCRC.  For more information, please contact 419.383.3801.

Last Updated: 6/26/14